Do analysts rate RDHL or SCNX?

Scienture has a consensus price target of $1.50, suggesting a potential upside of 221.96%. Given Scienture's stronger consensus rating and higher possible upside, analysts clearly believe Scienture is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is RDHL or SCNX more profitable?

Redhill Biopharma's return on equity of 0.00% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Scienture N/A -51.84% -42.22%

Does the media prefer RDHL or SCNX?

In the previous week, Scienture had 5 more articles in the media than Redhill Biopharma. MarketBeat recorded 8 mentions for Scienture and 3 mentions for Redhill Biopharma. Scienture's average media sentiment score of 0.98 beat Redhill Biopharma's score of 0.37 indicating that Scienture is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scienture 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RDHL or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer RDHL or BFRI?

In the previous week, Biofrontera had 8 more articles in the media than Redhill Biopharma. MarketBeat recorded 11 mentions for Biofrontera and 3 mentions for Redhill Biopharma. Biofrontera's average media sentiment score of 0.75 beat Redhill Biopharma's score of 0.37 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biofrontera 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RDHL or CABR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is RDHL or CABR more profitable?

Redhill Biopharma's return on equity of 0.00% beat Caring Brands' return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Caring Brands N/A -862.39% -302.23%

Do analysts prefer GRTX or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRTX or RDHL more profitable?

Company Net Margins Return on Equity Return on Assets Galera Therapeutics N/A N/A -99.34% Redhill Biopharma N/A N/A N/A

Do analysts rate RDHL or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is RDHL or COCP more profitable?

Redhill Biopharma's return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Cocrystal Pharma N/A -164.57% -108.08%

Redhill Biopharma (RDHL) Competitors

$0.58 -0.02 (-2.86%)

Closing price 03:58 PM Eastern

Extended Trading

$0.58 +0.00 (+0.52%)

As of 07:55 PM Eastern

Compare

RDHL vs. SCNX, BFRI, CABR, GRTX, and COCP

Should you buy Redhill Biopharma stock or one of its competitors? Redhill Biopharma's main competitors and comparable companies include Scienture (SCNX), Biofrontera (BFRI), Caring Brands (CABR), Galera Therapeutics (GRTX), and Cocrystal Pharma (COCP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Redhill Biopharma compare to Scienture?

Redhill Biopharma (NASDAQ:RDHL) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Redhill Biopharma's return on equity of 0.00% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Scienture	N/A	-51.84%	-42.22%

Redhill Biopharma has a beta of 5, meaning that its share price is 400% more volatile than the broader market. Comparatively, Scienture has a beta of 3.26, meaning that its share price is 226% more volatile than the broader market.

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 21.4% of Scienture shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Redhill Biopharma has higher earnings, but lower revenue than Scienture. Scienture is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	12.12	-$430K	$900.00	0.00
Scienture	$477.68K	39.63	-$41.51M	-$2.10	N/A

In the previous week, Scienture had 5 more articles in the media than Redhill Biopharma. MarketBeat recorded 8 mentions for Scienture and 3 mentions for Redhill Biopharma. Scienture's average media sentiment score of 0.98 beat Redhill Biopharma's score of 0.37 indicating that Scienture is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scienture	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scienture has a consensus price target of $1.50, suggesting a potential upside of 221.96%. Given Scienture's stronger consensus rating and higher possible upside, analysts clearly believe Scienture is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Scienture beats Redhill Biopharma on 8 of the 15 factors compared between the two stocks.

How does Redhill Biopharma compare to Biofrontera?

Redhill Biopharma (NASDAQ:RDHL) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Redhill Biopharma has higher earnings, but lower revenue than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	12.12	-$430K	$900.00	0.00
Biofrontera	$41.71M	0.40	-$10.54M	-$0.97	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Biofrontera had 8 more articles in the media than Redhill Biopharma. MarketBeat recorded 11 mentions for Biofrontera and 3 mentions for Redhill Biopharma. Biofrontera's average media sentiment score of 0.75 beat Redhill Biopharma's score of 0.37 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biofrontera	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Redhill Biopharma has a beta of 5, indicating that its stock price is 400% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by company insiders. Comparatively, 8.1% of Biofrontera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Redhill Biopharma has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Redhill Biopharma's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Biofrontera	-13.78%	-155.98%	-31.69%

Summary

Redhill Biopharma beats Biofrontera on 8 of the 15 factors compared between the two stocks.

How does Redhill Biopharma compare to Caring Brands?

Redhill Biopharma (NASDAQ:RDHL) and Caring Brands (NASDAQ:CABR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

7.2% of Redhill Biopharma shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 14.6% of Caring Brands shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Redhill Biopharma's return on equity of 0.00% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Caring Brands	N/A	-862.39%	-302.23%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has higher revenue and earnings than Caring Brands. Caring Brands is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	12.12	-$430K	$900.00	0.00
Caring Brands	N/A	N/A	-$6.28M	-$0.64	N/A

In the previous week, Redhill Biopharma and Redhill Biopharma both had 3 articles in the media. Caring Brands' average media sentiment score of 1.53 beat Redhill Biopharma's score of 0.37 indicating that Caring Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Caring Brands	Very Positive

Summary

Redhill Biopharma beats Caring Brands on 6 of the 8 factors compared between the two stocks.

How does Redhill Biopharma compare to Galera Therapeutics?

Galera Therapeutics (NASDAQ:GRTX) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Redhill Biopharma has higher revenue and earnings than Galera Therapeutics. Redhill Biopharma is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14
Redhill Biopharma	$290K	12.12	-$430K	$900.00	0.00

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
Redhill Biopharma	N/A	N/A	N/A

In the previous week, Redhill Biopharma had 3 more articles in the media than Galera Therapeutics. MarketBeat recorded 3 mentions for Redhill Biopharma and 0 mentions for Galera Therapeutics. Redhill Biopharma's average media sentiment score of 0.37 beat Galera Therapeutics' score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Galera Therapeutics	Neutral
Redhill Biopharma	Neutral

Galera Therapeutics has a beta of 2.6, suggesting that its stock price is 160% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 5, suggesting that its stock price is 400% more volatile than the broader market.

50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Redhill Biopharma beats Galera Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Redhill Biopharma compare to Cocrystal Pharma?

Redhill Biopharma (NASDAQ:RDHL) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Redhill Biopharma has a beta of 5, indicating that its stock price is 400% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

In the previous week, Redhill Biopharma had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for Redhill Biopharma and 2 mentions for Cocrystal Pharma. Redhill Biopharma's average media sentiment score of 0.37 beat Cocrystal Pharma's score of -0.56 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Cocrystal Pharma	Negative

Redhill Biopharma has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	12.12	-$430K	$900.00	0.00
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Redhill Biopharma's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Cocrystal Pharma	N/A	-164.57%	-108.08%

Summary

Redhill Biopharma beats Cocrystal Pharma on 10 of the 11 factors compared between the two stocks.

Get Redhill Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDHL vs. The Competition

Export

Metric	Redhill Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.62M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	0.00	640.15	211.09	21.74
Price / Sales	12.12	743.87	602.98	92.99
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	0.70	11.60	12.91	6.24
Net Income	-$430K	$2.77B	$3.45B	$347.60M
7 Day Performance	-4.46%	0.17%	1.12%	1.07%
1 Month Performance	-21.79%	0.35%	1.79%	1.03%
1 Year Performance	-59.01%	161.52%	67.69%	20.77%

Redhill Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDHL Redhill Biopharma	1.1176 of 5 stars	$0.58 -2.9%	N/A	-57.2%	$3.62M	$290K	0.00	210	News Coverage Upcoming Earnings Short Interest Increase Gap Down
SCNX Scienture	2.9939 of 5 stars	$0.38 -2.8%	$1.50 +298.9%	-79.1%	$15.72M	$430K	N/A	N/A	News Coverage Earnings Report Short Interest Decrease Gap Down
BFRI Biofrontera	0.9536 of 5 stars	$1.22 +2.5%	N/A	+32.6%	$15.24M	$41.71M	N/A	70	News Coverage Earnings Report Short Interest Increase
CABR Caring Brands	0.9283 of 5 stars	$1.56 -2.8%	N/A	N/A	$14.59M	N/A	N/A	4	Earnings Report Short Interest Decrease
GRTX Galera Therapeutics	N/A	$0.09 flat	N/A	+289.4%	$14.12M	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RDHL) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Redhill Biopharma (RDHL) Competitors

RDHL vs. SCNX, BFRI, CABR, GRTX, and COCP

How does Redhill Biopharma compare to Scienture?

Summary

How does Redhill Biopharma compare to Biofrontera?

Summary

How does Redhill Biopharma compare to Caring Brands?

Summary

How does Redhill Biopharma compare to Galera Therapeutics?

Summary

How does Redhill Biopharma compare to Cocrystal Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Redhill Biopharma (RDHL) Competitors

RDHL vs. SCNX, BFRI, CABR, GRTX, and COCP

How does Redhill Biopharma compare to Scienture?

Is RDHL or SCNX more profitable?

Which has more risk and volatility, RDHL or SCNX?

Do insiders & institutionals hold more shares of RDHL or SCNX?

Which has preferable earnings & valuation, RDHL or SCNX?

Does the media prefer RDHL or SCNX?

Do analysts rate RDHL or SCNX?

Summary

How does Redhill Biopharma compare to Biofrontera?

Which has stronger earnings and valuation, RDHL or BFRI?

Do analysts prefer RDHL or BFRI?

Does the media prefer RDHL or BFRI?

Which has more risk and volatility, RDHL or BFRI?

Do insiders and institutionals hold more shares of RDHL or BFRI?

Is RDHL or BFRI more profitable?

Summary

How does Redhill Biopharma compare to Caring Brands?

Do institutionals & insiders hold more shares of RDHL or CABR?

Is RDHL or CABR more profitable?

Do analysts prefer RDHL or CABR?

Which has better valuation and earnings, RDHL or CABR?

Does the media refer more to RDHL or CABR?

Summary

How does Redhill Biopharma compare to Galera Therapeutics?

Which has better valuation & earnings, GRTX or RDHL?

Do analysts prefer GRTX or RDHL?

Is GRTX or RDHL more profitable?

Does the media favor GRTX or RDHL?

Which has more risk & volatility, GRTX or RDHL?

Do institutionals and insiders have more ownership in GRTX or RDHL?

Summary

How does Redhill Biopharma compare to Cocrystal Pharma?

Which has more volatility and risk, RDHL or COCP?

Does the media prefer RDHL or COCP?

Which has higher valuation and earnings, RDHL or COCP?

Do analysts rate RDHL or COCP?

Do insiders & institutionals believe in RDHL or COCP?

Is RDHL or COCP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools